a

Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development.

Events

Visit us at our upcomming events.

Contact us

Who we are

Toxys is a Dutch biotech company that provides innovative in vitro toxicity screening solutions to rapidly identify hazardous and potential carcinogenic properties of novel compounds during the early phases of product and drug development. We aim to bring information to our customers that is essential to make informed decisions on which compounds to progress in the drug/compound development pipeline, thereby contributing to the development of better medicines and products and to reduce animal testing. We offer services in the following fields:

Genetic Toxicology

We have extensive experience and knowhow in the field of Genetic Toxicology. We often combine our unique ToxTracker assay with a range of extended protocols and additional assays to unravel the underlying mechanism of genotoxicity and predict the outcomes in the regulatory in vitro and in vivo genotoxicity assays.

Read more

Reproductive Toxicology

By combining our expertise in stem cell technologies and reporter systems, we have generated ReproTracker, an in vitro assay that is able to visualise key processes in the early embryonic development. The assay can be applied to assess developmental toxicology in the early phases of drug development.

Read more

Mechanistic Toxicology

All assays that are developed at Toxys are aimed at understanding the mechanism underlying toxicity. We believe that this mechanistic understanding is key to translate the results from in vitro test systems to a relevance for humans. These mechanism-based test systems can be particularly useful in an Adverse Outcome Pathway (AOP) approach for both genotoxic and non-genotoxic carcinogens and in the development of an Integrated Approach to Testing and Assessment (IATA).

Read more

Toxys in 90 seconds

This video gives you a quick insight into what Toxys could do for you.

Read More

Happy Customers

We work together with a growing number of customers from different industries ranging from pharmaceutical companies to chemical and consumer-goods companies and from large size companies to small start-ups. We offer unique in-house screening capabilities combined with the responsiveness and flexibility found only in smaller companies. Please read what some of our customers said about working together:

Peter Boogaard
Shell

"Mechanism-based screening assays like the ToxTracker can make a valuable contribution to the routine safety compliance screening of our products"

Jacky van Gompel

“A succesfull genotoxicity screening strategy is always dependent on the availability of mechanism of action data, as this will provide a link towards risk assessment. The Toxtracker assay is able to provide this relevant information fast and reliable so that the medicinal chemist is able to drive his chemistry plan into the safe zone.”

Diels van den Dobbelsteen
Synthon

"The ToxTracker assay is an excellent tool to evaluate the genotoxic potential of compounds, generating great additional value by dissecting the underlying genotoxic mechanisms, and thereby better assess the relevance of the genotoxic response in a fast and cost-efficient manner.”

Pekka Heikkinen
Orion

"Orion has worked successfully with Toxys on a couple of occasions. We are happy with the open communication which makes planning the experiments and interpreting the results easy and straightforward. The assay is excellent follow-up for our in-house micronucleus test to reveal the mode-of-action and hence validate or in-validate the borderline positive/negative dilemma."

David Kirkland
Kirkland Consultancy

“In regulatory assessment of carcinogenic or germ cell mutagenic risk, it is becoming increasingly important to understand mode of action, and not just rely on weight of negative evidence from in vivo genotoxicity studies to overrule positive in vitro genotoxicity results. To this end, there is increasing demand for integrated mechanism-based assays like ToxTracker as essential components in the development of safe and specific drugs or products.”

Paula van Rossum

Toxys has been awarded Innovation Credit to further develop ReproTracker

Leiden 20 September 2017 - Today Toxys was awarded an Innovation Credit from RVO to accelerate the develop of the ReproTracker assay. ReproTracker® is a state-of-the-art in vitro reporter assay to rapidly identify compounds that disturb stem cell differentiation and early embryonic development. Testing for...

Paula van Rossum

European patent for ToxTracker granted

6 July 2017 - Leiden, the Netherlands - Toxys is proud to announce that next to the US patent which already was granted, the European patent for ToxTracker, an unique genotoxicity assay, has been granted.About ToxTracker ToxTracker® assay is a state-of-the-art stem cell-based reporter assay that...

Paula van Rossum

Toxys launches large international validation study for ToxTracker

Leiden,  1 May 2017 - Together with a consortium of leading experts in the field of genotoxicity, Toxys has started a large inter-laboratory validation study for their ToxTracker assay. With this study, Toxys aims to demonstrate the transferability, intra- and inter-laboratory reproducibility as well as...

Paula van Rossum

Poster together with P&G presented at the SOT 2017: use of multiparametric mode of action approaches for genetic toxicity assessment

This poster describes the investigation of several different predictive, animal-free genetic toxicology methodologies with varying degrees of complexity. The predictive capacity of these methods was compared by testing 22 chemicals that represent a mix of DNA reactive chemicals, chemicals with known, mixed or unknown modes...

ICEM-ACEM 2017

Please meet us at the 12th International Conference and 5th Asian Congress on Environmental Mutagens (ICEM-ACEM 2017) in Korea.